abveris

A Division of Twist Bioscience

ABOUT

ABVERIS ANTIBODY DISCOVERY

WHO WE ARE: As a division of Twist Biopharma, Abveris provides exceptional *in vivo* antibody discovery services across the board, from project design and communication to final product delivery, by leveraging the superior epitopic coverage of the best-in-class hyperimmune mouse model, DiversimAb™, advanced screening methods, and cutting-edge engineering platforms of Twist Biopharma. Our discovery platform is advantaegously designed for:

- High Speed mAb Discovery (as little as 29 days from immunization to delivery of mAb sequences)
- Top Quality Offerings
- Dedicated, Expert-Level Project Managers
- Exceptional Epitopic & Sequence Diversity
- Fee-for-Service Provider With no Milestones or Royalties

TRACK RECORD OF SUCCESS:

- 100+ Successful Cell Surface Targeting mAb Campaigns
- 150+ Successful Anti-Idiotype mAb Discovery Campaigns
- 7+ Programs That Have Proceeded to Clinical Trials
- 80%+ of Partners Have Returned for Additional Projects

OUR DISCOVERY WORKFLOWS



Find out more at:

www.abveris.com | www.twistbiopharma.com

WHAT WE OFFER

Therapeutic Antibody (IgG, bsAb, ADC) Lead Discovery

- Human (through transgenic humanized mice) and murine antibody discovery (through DiversimAb™ mice)
- VHH and scFv discovery for bispecific antibodies
- Proven expertise for cell surface receptors, GPCRs, and ion channels
- Function-forward, high-throughput workflows that deliver rare, functional mAbs
- Rapid humanization and developability assessment options
- Ultra-fast, high-resolution single B cell workflow that enables the identification of mAb sequences from starting of immunization in as few as 29 days

Chimeric Antigen Receptor (CAR) Construct Lead Discovery

- *In vivo* discovery of the ectodomain in CAR constructs for cell-based therapeutics
- Function-forward workflows to validate on-cell binding
- Diverse range of affinities warranted by the DiversimAb™ technology
- Flexible project deliverables: sequences and/or purified, validated scFv or VHH
- Optimization of transmembrane domain and endodomain by Twist library approach

Reagent/Anti-Idiotypic Antibody Discovery for PK/ADA Assays

- Guaranteed delivery of specific blockers
- Rapid and reliable project timelines: hybridoma and single B cell workflow
- Flexible project deliverables: mAb validation (ELISA, Octet, SPR, flow) and purification (hybridoma or recombinant mAb up to 100mg)
- Experience targeting a wide range of therapeutic modalities: IgG, IgM, bsAb, sdAb, ADC, scFv, CARs, small molecules
- Stringent screening cascades to ensure the delivery of ideal, assay-ready reagents to support clinical trials

Enhanced Epitopic Diversity via Proprietary Hyperimmune Mouse Models

- Expanded repertoire diversity and broadened epitopic coverage including non-immunodominant epitopes via our proprietary hyperimmune mouse family, **DiversimAb™**
- Broken tolerance and robust immune response against highly conserved antigens
- Delivery of strong, antigen-specific titer within 3 weeks under rapid immunization schedules
- Ideal for the discovery of mAb against cell surface targets, species cross-reactive mAbs (ex: human/cyno/murine cross-reactive), and mouse-mouse surrogates

Wild-Type Mouse



DiversimAb™ Mouse



480 Neponset Street, Suite 10B, Canton, MA 02021, USA | abveris.com | (781) 562-1170